SCHEMBL6461074

SCHEMBL6461074

O=C(Nc1nccc2oc(CO)cc12)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.46
CSF1R P07333 1/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
ADORA3 P0DMS8 4/20 0.43
HTT P42858 1/20 0.42
ALDH1A1 P00352 3/20 0.40
HPGD P15428 2/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HDAC6 Q9UBN7 1/20 0.39
KMT2A Q03164 1/20 0.39
KCNK3 O14649 1/20 0.39
KCNK9 Q9NPC2 1/20 0.39
ABCG2 Q9UNQ0 1/20 0.39
POLB P06746 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
JAK2 O60674 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1768883 0.80 MET (0.46) METNPC1RAB9AADORA3HTT
SCHEMBL1769014 0.80 MET (0.41) METCSF1RNPC1RAB9AADORA3
SCHEMBL6453679 0.76 CSF1R (0.47) CSF1RNPC1RAB9AADORA3HTT
SCHEMBL1768997 0.76 NPC1 (0.49) NPC1RAB9AADORA3HTTSMN1; SMN2
SCHEMBL6438858 0.74 CSF1R (0.54) CSF1RNPC1RAB9AADORA3HTT
SCHEMBL6435363 0.73 CSF1R (0.53) CSF1RNPC1RAB9AADORA3HTT
SCHEMBL12649894 0.72 MET (0.42) METNPC1RAB9AADORA3HTT
SCHEMBL1768972 0.72 MET (0.42) METNPC1RAB9AADORA3HTT
SCHEMBL5874038 0.71 ADORA3 (0.62) NPC1RAB9AADORA3HTTKMT2A
SCHEMBL1768941 0.71 ALDH1A1 (0.45) METNPC1RAB9AADORA3HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1505062-A1 Heterocyclic derivatives and their use as antithrombotic agents Akzo Nobel N.V. (NL) 2005-02-09 EP disclosed
US-6797710-B2 CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY AKZO NOBEL N.V. (NL) 2004-09-28 US disclosed
US-20030130270-A1 Heterocyclic derivatives and their use as antithrombotic agents MERCK SHARP & DOHME B.V. (NL) 2003-07-10 US disclosed
US-6444672-B1 ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR AKZO NOBEL N.V. (NL) 2002-09-03 US disclosed
US-6432955-B1 ANTICOAGULANTS AKZO NOBEL N.V. (NL) 2002-08-13 US disclosed
US-6194409-B1 SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH AKZO NOBEL N.V. (NL) 2001-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130270-A1 Heterocyclic derivatives and their use as antithrombotic agents F2, F12, VKORC1 MET 4439/4885CSF1R 3030/4885NPC1 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.